Panel discussion
InnoMedica
Website: | www.innomedica.com |
Date: | April 22, 2024 |
Time: | 16:30-17:15 |
Room: | Sydney |
Panel title
Achieve initial market access in Switzerland.
Panel summary
Is initial market authorisation in neurology and oncology worth it in Switzerland?
The most critical and mandatory prerequisites for Switzerland as a biotech startup innovation location are discussed.
Join and discuss with us.
Speaker information
Moderation
Stephan Klapproth, Entrepreneur, Journalist and Moderator, former TV-Moderator
Panelists
Dr. med. Carlos Beat Quinto, Member of the FMH central board
Dr. Peter Halbherr, Chairman and General Manager, InnoMedica
Sylvia Schuepbach, Lawyer, Pharmalex
Pascal Strupler, Consultant and Partner, KMES Partner
Company profile
InnoMedica’s vision is to replace the systemic application of drugs with a targeted, and therefore gentler, approach by refining the most effective active ingredients into intelligent therapies using liposomal nanotechnology. The mission is therefore to enhance therapies for diseases with great therapeutic need, such as cancer, Parkinson’s or ALS, or to make therapy possible in the first place, in order to achieve real medical progress for the people affected.